Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

This document reports the completion and results posting of a Phase 2 trial evaluating the safety, tolerability, and efficacy of AIN457 in relapsing-remitting m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• AIN457

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2016-03-14